Skip to main content

Table 1 Distribution of RET single mutations in MEN2 with ATA-classified, demographic characteristics and the presence of MTC, PHEO, PHPT, CLA and HD

From: Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China

ATA-2015

Risk category

RET

mutation

Nucleotide change

Family

(No, %)

No. available

/ Carriers

Sex

(M/F)

MTC

PHEO

HPTH

CLA

HD

No. patient

(%)

MAD

(range, yrs)

No. patient

(%)

MAD

(range, yrs)

No. patient

(%)

MAD (range, yrs)

No. patient

(%)

MAD

(range,yrs)

No. patient

(%)

MAD

(range, yrs)

ATA-MOD

C609R

c.1825 T > C

1 (1.5)

1/1

0/1

1 (100)

52

–

–

–

–

–

–

–

–

C611Y

c.1832G > A

1 (1.5)

17/17

8/9

15 (88.2)

45.9 (23–74)

2 (12.5)

53 (37,69)

–

–

1 (6.3)

40

–

–

C611F

c.1832-1833delGCinsTT

1 (1.5)

1/1

1/0

0 (0)

–

1

32

1

32

–

–

–

–

C618G

c.1852 T > G

2 (3.1)

4/4

2/2

4 (100)

57.8 (37–83)

–

–

–

–

–

–

–

–

C618R

c.1852 T > C

4 (6.2)

25/25

6/19

24 (96)

40.3 (21–60)

2 (8)

57.5 (46,69)

1

60

–

–

1(4)

6+/−

C618S

c.1852 T > A

1 (1.5)

12/12

3/9

11 (91.2)

41.1 (24–59)

–

–

–

–

–

–

–

–

C618Y

c.1853G > A

1 (1.5)

9/9

3/6

8 (88.9)

55.3 (35–78)

–

–

–

–

–

–

–

–

C620R

c.1858 T > C

1 (1.5)

1/1

1/0

1 (100)

27

–

–

–

–

–

–

–

–

C620S

c.1859G > C

1 (1.5)

1/1

1/0

1 (100)

39 (39)

–

–

–

–

–

–

–

–

L790F

c.2370G > T

8 (12.3)

15/30a

11/19

14 (93.3)

46.1 (27–70)

–

–

–

–

–

–

–

–

V804M

c.2410G > A

4 (6.2)

4/4

4/0

4 (100)

50.7 (40–69)

–

–

–

–

–

–

–

–

S891A

c.2671 T > G

2 (3.1)

6/6

4/2

3 (50)

42 (25–62)

–

–

–

–

–

–

–

–

ATA-H

C634F

c.1901G > T

2 (3.1)

3/3

1/2

3 (100)

31.7 (8–58)

1 (33.3)

26 (26)

–

–

–

–

–

–

C634G

c.1900 T > G

2 (3.1)

7/7

3/4

7 (100)

52.2 (43–66)

3 (42.9)

54.6 (45–66)

–

–

3 (42.9)

54 (53,54,55)

–

–

C634R

c.1900 T > C

5 (7.7)

15/15

6/9

15 (100)

32.6 (18–65)

6 (40)

34 (21–47)

1

40

1 (6.3)

40

–

–

C634S

c.1900 T > A

1 (1.5)

3/3

2/1

3 (100)

61.3 (51–77)

–

–

–

–

–

–

–

–

C634W

c.1902C > G

1 (1.5)

1/1

0/1

1 (100)

34

1 (100)

34

1 (100)

34

1 (100)

34

–

–

C634Y

c.1901G > A

22 (33.8)

69/69

37/32

69 (100)

34.3 (5.5–80)

32 (46.3)

42 (18–75)

7 (10)

30 (15–55)

–

–

–

–

ATA-HST

M918T

c.2753 T > C

5 (7.7)

5/5

2/3

5 (100)

25.4(8–34)

2 (40)

36 (22–50)

–

–

–

–

–

–

Total

19

 

65 (100)

199/214

95/119

189 (95.0)b

40.5(5.5–83)c

50 (25.1)

41.9 (18–75)

11 (5.5)

34.2 (15–60)

6 (5.0)

42 (34–55)d

1 (0.5)

NA

  1. MEN2 multiple endocrine neoplasia type 2, ATA American Thyroid Association. Risk of aggressive MTC: MOD moderate, H high, HST highest, M Male, F Female, MTC medullary thyroid carcinoma, PHEO pheochromocytoma, HPTH hyperparathyroidism, CLA cutaneous lichen amyloidosis, HD Hirschsprung’s disease, AD average age of diagnosis, yrs. years, − negative, NA not available
  2. a The 15 other carriers rejected further clinical and biochemical/imaging examinations
  3. b 10 of the 199 MEN2 patients had no abnormality
  4. c The mean age at the time of MTC diagnosis in184 MEN2A patients was 38.09 ± 17.18 years
  5. d Mean age at onset of CLA was 20 yrs. (range, 12–26)